Abstract: This study aimed to investigate the protective effects of dexamethasone, aspirin and bromocriptine on hepatic ischemia/reperfusion-induced liver injury. About 60 male Wistar Albino rats were randomly assigned to 6 groups of 10 rats each. Group 1 served as negative control, group 2 served as hepatic I/R control injury. Rats in groups 3-6 received N-acetylcysteine (standard, 100 mg/kg/day, i.p.), dexamethasone (5 mg/kg/day, i.p.), aspirin (10 mg/kg/day, i.p.) and bromocriptine (10 mg/kg/day, i.p.), respectively for 3 consecutive days prior to ischemia. All animals were fasted for 12 h, anaesthetized with thiopental and underwent midline laparotomy. The portal vein, hepatic artery and bile duct (portal triad) were clamped by mini-artery clamp for 30 min followed by reperfusion for 30 min. At the end of the experiment, blood samples were withdrawn for estimation of serum Alanine Transaminase (ALT) and Aspartate Transaminase (AST) activities in addition to assessment of hepatic Thiobarbituric Acid Reactive Substances (TBARS), Glutathione (GSH), Myeloperoxidase (MPO) and total nitrate/nitrite (NO_x) production, as well as histopathological examination. Dexamethasone, aspirin and bromocriptine significantly ameliorated hepatic I/R injury as evidenced by significant reduction in serum ALT and AST enzyme activities. Dexamethasone, aspirin and bromocriptine markedly reduced hepatic oxidative stress biomarkers as compared to control I/R injury. The inflammatory mediators MPO and NO_x levels in liver were also significantly reduced after treatment with dexamethasone, aspirin and bromocriptine. In accordance, a marked improvement of histopathological findings was observed with any of the 3 treatments. Dexamethasone, = aspirin and bromocriptine seem to offer protection against hepatic ischemia/reperfusion-induced liver injury and are promising for further clinical trials.